Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First‐Line Helicobacter pylori Eradication: A Randomized Controlled Trial

Documenti analoghi

• Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial
  di: Xinlu Ren, et al.
  Pubblicazione: (2025)
• The Systemic Impact of Helicobacter pylori Infection on the Microbiome of Whole Digestive Tract Based on Mucosal, Gastric Juice, and Fecal Specimens
  di: Yuxin Wang, et al.
  Pubblicazione: (2025)
• Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article
  di: Changmin Mi, et al.
  Pubblicazione: (2024)
• Correction to “Long‐Term Effects of Fecal Microbiota Transplantation on Gut Microbiota After Helicobacter pylori Eradication With Bismuth Quadruple Therapy: A Randomized Controlled Trial”
  Pubblicazione: (2024)
• Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial”
  di: Zhengchen Yu, et al.
  Pubblicazione: (2025)